N-((4-chlorophenyl)carbamoyl)benzamide | 57160-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-((4-chlorophenyl)carbamoyl)benzamide
• 英文别名: N-benzoyl-N'-(4-chloro-phenyl)-urea；N-Benzoyl-N'-(4-chlor-phenyl)-harnstoff；N-[(4-chlorophenyl)carbamoyl]benzamide
• CAS: 57160-46-0
• 化学式: C₁₄H₁₁ClN₂O₂
• 分子量: 274.707
• InChiKey: MQYMKWNLXXZZBH-UHFFFAOYSA-N

物化性质

• 熔点：
  232 °C
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  哌啶 、 N-((4-chlorophenyl)carbamoyl)benzamide 以 1,4-二氧六环 为溶剂， 反应 2.5h， 以25.1%的产率得到N-Benzoyl-N',N'-pentamethylen-harnstoff
  参考文献：
  名称：

  N-酰基脲及其对胺的反应

  摘要：

  一些 N-酰基脲不仅在与胺的裂解反应中产生与游离异氰酸酯相同的产物，而且还表现出许多意想不到的反应，这取决于亲核试剂的碱性和取代基的电子影响。

  DOI：

  10.1002/ardp.19863190908
• 作为产物：
  描述：

  N-[(4-氯苯基氨基)(硫代羰基)]苯甲酰胺 在 1-氧杂-2-氮杂螺[2.5]辛烷 作用下， 以 甲苯 为溶剂， 反应 4.0h， 生成 N-((4-chlorophenyl)carbamoyl)benzamide
  参考文献：
  名称：

  Andreae, Siegfried; Schmitz, Ernst, Journal fur praktische Chemie (Leipzig 1954), 1987, vol. 329, # 6, p. 1008 - 1014

  摘要：

  DOI：

文献信息

• Pd-Catalyzed Carbonylation of Acyl Azides
  作者：Zongyang Li、Shiyang Xu、Baoliang Huang、Chenhui Yuan、Wenxu Chang、Bin Fu、Lei Jiao、Peng Wang、Zhenhua Zhang

  DOI：10.1021/acs.joc.9b01048

  日期：2019.8.2

  provides facile access to acyl ureas. In addition, a mechanistic study was carried out by both experiment and DFT calculation. Control experiments and kinetic study revealed that the real active palladium species were Pd(0). The result of kinetic study suggested that palladium catalyst, azide, and CO were all involved in the turnover-limiting step except for amine. Further DFT study suggested that an

  近年来，已广泛开发了Pd催化的叠氮化物与CO反应生成异氰酸酯中间体的方法。然而，尚未报道敏感的酰基叠氮化物的催化羰基化。在本文中，我们报道了酰基叠氮化物的简单Pd催化羰基化反应，具有广泛的底物范围，高效率以及在温和条件下的简单操作，可轻松获得酰基脲。此外，还通过实验和DFT计算进行了机理研究。对照实验和动力学研究表明，真正的活性钯物质为Pd（0）。动力学研究的结果表明，除胺外，钯催化剂，叠氮化物和一氧化碳都参与了营业额限制步骤。
• Pharmaceutical compositions containing benzoyl-phenyl ureas with anti-tumour activity
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0107214A2

  公开（公告）日：1984-05-02

  A method of and composition suitable for combating tumors in mammals is disclosed, characterized in that a therapeutically effective quantity of at least one 1-benzoyl-3-phenyl ureas or a metabolite thereof, which compounds are known per se, is administered in a pharmaceutically acceptable carrier.

  本发明公开了一种适用于抗击哺乳动物肿瘤的方法和组合物，其特征在于将治疗有效量的至少一种 1-苯甲酰基-3-苯基脲或其代谢物（这些化合物本身是已知的）置于药学上可接受的载体中给药。
• Benzoyl urea derivatives having ati-tumor activity
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0193249A2

  公开（公告）日：1986-09-03

  The present invention relates to a group of new benzoyl urea derivatives of the formula having a better antitumor activity in comparison with known benzoyl urea derivatives. The compounds have been tested in several in vitro test models with different types of tumors.

  本发明涉及一组新的苯甲酰脲衍生物，其式为 与已知的苯甲酰脲衍生物相比，具有更好的抗肿瘤活性。这些化合物已在几种不同类型肿瘤的体外试验模型中进行了测试。
• Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships
  作者：J. Jeffry Howbert、C. Sue Grossman、Thomas A. Crowell、Brent J. Rieder、Richard W. Harper、Kenneth E. Kramer、Eddie V. Tao、James Aikins、Gerald A. Poore

  DOI：10.1021/jm00171a013

  日期：1990.9

  A series of diarylsulfonylureas with exceptionally broad-spectrum activity against syngeneic rodent solid tumors in vivo is described. Their discovery resulted from a program dedicated to in vivo screening for novel oncolytics in solid tumor models, rather than traditional ascites leukemia models. The structures, oral efficacy, side-effect profile, and mechanism of action of these sulfonylureas appear to be distinct from previously known classes of oncolytics. An extensive series of analogues was prepared to probe structure-activity relationships (SAR), with particular focus on the substituent patterns of each aryl domain. Quantitative analysis of these substituent SARs, using the method of cluster significance analysis, showed the lipophilicity of the substituents to be the dominant determinant of activity. One compound from the series, LY186641 (104, sulofenur), has progressed to Phase I clinical trials as an antitumor drug.
• A Study on the Stability of 5,5-Diamino-substituted-1,4,2-oxathiazoline Derivatives
  作者：Keum Shin Jung、Hong Jung Lee、Hyun Nam Song、Jae Nyoung Kim

  DOI：10.1080/00397919808007019

  日期：1998.5

  5,5-Diamino-substituted-1,4,2-oxathiazoline derivatives 3 as potential prodrugs, which were easily prepared from hydroximoyl chlorides 1 and the appropriate thiourea derivatives 2, were decomposed instantaneously into isothiocyanates 4 and the corresponding urea derivatives 5 irrespective of the substituents.